Larson Financial Group LLC Acquires 8,249 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Larson Financial Group LLC grew its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 1,649.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,749 shares of the biotechnology company’s stock after purchasing an additional 8,249 shares during the period. Larson Financial Group LLC’s holdings in Sarepta Therapeutics were worth $1,093,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Farallon Capital Management LLC increased its holdings in Sarepta Therapeutics by 102.8% in the 1st quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock worth $317,630,000 after buying an additional 1,243,427 shares in the last quarter. Thrivent Financial for Lutherans grew its stake in shares of Sarepta Therapeutics by 6.3% in the second quarter. Thrivent Financial for Lutherans now owns 644,675 shares of the biotechnology company’s stock worth $101,858,000 after acquiring an additional 37,940 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in shares of Sarepta Therapeutics by 1.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 611,749 shares of the biotechnology company’s stock valued at $76,401,000 after purchasing an additional 6,992 shares during the last quarter. abrdn plc lifted its position in Sarepta Therapeutics by 30.7% during the third quarter. abrdn plc now owns 431,098 shares of the biotechnology company’s stock valued at $53,935,000 after purchasing an additional 101,253 shares during the period. Finally, Mizuho Markets Americas LLC boosted its holdings in Sarepta Therapeutics by 22.3% in the third quarter. Mizuho Markets Americas LLC now owns 399,065 shares of the biotechnology company’s stock worth $49,839,000 after purchasing an additional 72,765 shares during the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Trading Up 3.4 %

SRPT stock opened at $114.23 on Monday. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. Sarepta Therapeutics, Inc. has a 1-year low of $78.67 and a 1-year high of $173.25. The business has a 50 day simple moving average of $122.00 and a two-hundred day simple moving average of $131.52. The company has a market capitalization of $10.91 billion, a price-to-earnings ratio of 91.38 and a beta of 0.81.

Wall Street Analysts Forecast Growth

SRPT has been the subject of a number of research reports. StockNews.com lowered shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, November 20th. Royal Bank of Canada reiterated an “outperform” rating and set a $182.00 price objective on shares of Sarepta Therapeutics in a research report on Monday, October 21st. Guggenheim raised their target price on Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. William Blair raised shares of Sarepta Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Finally, Barclays lowered their price objective on shares of Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating on the stock in a research note on Thursday, August 8th. Two equities research analysts have rated the stock with a hold rating, twenty have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $181.33.

Insider Buying and Selling

In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 5,985 shares of the business’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the sale, the chief financial officer now owns 33,946 shares in the company, valued at $4,662,822.56. The trade was a 14.99 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 7.70% of the stock is owned by company insiders.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.